LungLife AI, Inc.

LSE LLAI.L

LungLife AI, Inc. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD 4.95 M

LungLife AI, Inc. Net Cash Used For Investing Activities is USD 4.95 M for the year ending December 31, 2023, a 4,406.09% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

LungLife AI, Inc. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -115.00 K, a 93.60% change year over year.
LungLife AI, Inc. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -1.80 M, a -33,609.18% change year over year.
LungLife AI, Inc. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -5.33 K, a 94.20% change year over year.
LungLife AI, Inc. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -91.91 K, a -105.24% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

LSE: LLAI.L

LungLife AI, Inc.

CEO	Dr. Paul Pagano Ph.D.
IPO Date	July 8, 2021
Location	United States
Headquarters	2545 West Hillcrest Drive
Employees	8
Sector	Healthcare
Industries Biotechnology 3D Printing Artificial Intelligence (AI) Autonomous Driving Drones Hardware & Electronics Medical Instruments Robotics

Description

LungLife AI, Inc., a cancer diagnostics company, develops clinical diagnostic solutions for lung cancer with artificial intelligence (AI) technology. It engages in developing LungLB, an AI enhanced, blood-based test to utilize machine learning to identify and count CTCs with reducing operator hands-on time and increasing test performance. The company was formerly known as Cynvenio Biosystems, Inc. and changed its name to LungLife AI, Inc. in May 2019. The company is based in Thousand Oaks, California.

Key trends

Past 5 years